Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events.

Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, Rimm EB, Willett WC, Fuchs CS.

Circulation. 2006 Mar 28;113(12):1578-87. Epub 2006 Mar 13.

2.

Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.

Rostom A, Dubé C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D; U.S. Preventive Services Task Force.

Ann Intern Med. 2007 Mar 6;146(5):376-89. Review.

PMID:
17339623
3.

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.

Brown TJ, Hooper L, Elliott RA, Payne K, Webb R, Roberts C, Rostom A, Symmons D.

Health Technol Assess. 2006 Oct;10(38):iii-iv, xi-xiii, 1-183. Review.

4.

COX-2 selective inhibitors in the treatment of osteoarthritis.

Laine L, White WB, Rostom A, Hochberg M.

Semin Arthritis Rheum. 2008 Dec;38(3):165-87. doi: 10.1016/j.semarthrit.2007.10.004. Epub 2008 Jan 4. Review.

PMID:
18177922
5.

Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs.

Hermann M.

Curr Rheumatol Rep. 2009 Feb;11(1):31-5. Review.

PMID:
19171109
6.

Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.

Joshi GP, Gertler R, Fricker R.

Anesth Analg. 2007 Dec;105(6):1793-804, table of contents. Review.

PMID:
18042885
7.
8.

Cardiovascular risk, hypertension, and NSAIDs.

White WB.

Curr Rheumatol Rep. 2007 Apr;9(1):36-43. Review.

PMID:
17437665
9.

Cardiovascular risk, hypertension, and NSAIDs.

White WB.

Curr Pain Headache Rep. 2007 Dec;11(6):428-35. Review.

PMID:
18173977
10.

The use of NSAIDs in rheumatic disorders 2005: a global perspective.

Kean WF, Buchanan WW.

Inflammopharmacology. 2005;13(4):343-70. Review.

PMID:
16354389
12.

Use of non-aspirin nonsteroidal antiinflammatory drugs and the risk of cardiovascular events.

Cheng JW.

Ann Pharmacother. 2006 Oct;40(10):1785-96. Epub 2006 Sep 19. Review.

PMID:
16985093
13.

Selectivity of NSAIDs for COX-2 and cardiovascular outcome.

Maxwell SR, Payne RA, Murray GD, Webb DJ.

Br J Clin Pharmacol. 2006 Aug;62(2):243-5. Review.

14.

Nonselective nonsteroidal antiinflammatory drugs and cardiovascular risk: are they safe?

Waksman JC, Brody A, Phillips SD.

Ann Pharmacother. 2007 Jul;41(7):1163-73. Epub 2007 Jul 3. Review.

PMID:
17609238
15.

Nonsteroidal antiinflammatory drugs, acetaminophen, and hypertension.

Sudano I, Flammer AJ, Roas S, Enseleit F, Noll G, Ruschitzka F.

Curr Hypertens Rep. 2012 Aug;14(4):304-9. doi: 10.1007/s11906-012-0274-7. Review.

PMID:
22610476
16.

Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.

Dajani EZ, Islam K.

J Physiol Pharmacol. 2008 Aug;59 Suppl 2:117-33. Review.

17.

Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.

Chaiamnuay S, Allison JJ, Curtis JR.

Am J Health Syst Pharm. 2006 Oct 1;63(19):1837-51. Review.

PMID:
16990630
18.

The NSAID dilemma: managing osteoarthritis in high-risk patients.

Roth SH, Anderson S.

Phys Sportsmed. 2011 Sep;39(3):62-74. doi: 10.3810/psm.2011.09.1922. Review.

PMID:
22030942
19.

[What do we know about the cardiovascular toxicity of the NSAIDs?].

Sibilia J, Deray G, Montalescot G.

Presse Med. 2006 Sep;35(9 Spec No 1):1S11-23. Review. French.

PMID:
17078591
20.

Areas of emerging interest in analgesia: cardiovascular complications.

Hillis WS.

Am J Ther. 2002 May-Jun;9(3):259-69. Review.

PMID:
11941385
Items per page

Supplemental Content

Write to the Help Desk